Fulgent Genetics, Inc. FLGT Therapeutic Development — Investment Income Interest

Other segment segments

Laboratory Services

$8.65M+7.9%

Similar metrics at other companies

DNLITherapeutics Segment — Interest and other income, net

$8.91M-29.3%

LINCInvestment Income Interest

$30K-73.7%

LGNDDevelopment and Licensing of Biopharmaceutical Assets — Interest Income

$6.66M+276%

KNSAPharmaceutical — Investment Income Interest

$3.41M+49.1%

KBO

KBONInvestment Income Interest

$3.07M—

RRInvestment Income Interest

$3.4M+921%

Other financials

Income statement

See full

Revenue$71.1M-3.2%

Gross profit$21.5M-24.2%

Operating income-$34.6M-74.9%

Net income-$24.8M-115%

EPS (diluted)-$0.80-116%

Balance sheet

See full

Cash & equivalents$23.4M-65.2%

Total debt$8.2M+40.5%

Total equity$1.0B-6.9%

Total assets$1.2B-4.1%

Cash flow

See full

Operating cash flow$7.1M+260%

CapEx$5.2M+10.3%

Free cash flow$1.9M+121%

Valuation

See full

Market cap$552.11M-7.1%

Enterprise value$536.92M+0.7%

P/S1.7×-0.3×

Profitability

See full

Gross margin38.7%-0.1pp

Operating margin-33.1%+17.4pp

Net margin-23%+43.3pp

FCF margin-36.9%—

Returns & leverage

See full

Return on equity-6.8%+48.2pp

Debt / equity0×0.0×

Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — investment income interest.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s therapeutic development — investment income interest?: Fulgent Genetics, Inc. (FLGT) reported therapeutic development — investment income interest of $0 in Q1 2026.
What does therapeutic development — investment income interest mean?: This captures interest income generated from cash or financial assets specifically allocated to the therapeutic development segment. It provides insight into the segment's ability to generate returns on its available capital resources.